Report of Nine Cases of Embryonal Tumors of the Central Nervous System with Multilayered Rosettes (ETMR)

IF 6.5 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijrobp.2024.11.039
R. Ai , J. Li , M. Lai , R. Al
{"title":"Report of Nine Cases of Embryonal Tumors of the Central Nervous System with Multilayered Rosettes (ETMR)","authors":"R. Ai ,&nbsp;J. Li ,&nbsp;M. Lai ,&nbsp;R. Al","doi":"10.1016/j.ijrobp.2024.11.039","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Embryonal Tumors of the Central Nervous System with Multilayered Rosettes (ETMR) are rare, and there's no standard treatment protocol. This article reports on the current treatment status and prognosis of ETMR in our hospital.</div></div><div><h3>Methods</h3><div>We retrospectively collected patients with ETMR who received treatment in the Oncology Department of Guangdong sanjiu Brain Hospital from January 2017 to January 2021, analyzed their clinical data.</div></div><div><h3>Results</h3><div>Among 31 cases of central nervous system embryonic tumors (excluding medulloblastoma and ATRT), 9 (29.03%) were ETMR. The median age at diagnosis was 3 years old (1-15), and the male to female ratio was 4:5. Among them, 5 cases were accompanied by C19MC gene variation. Tumor location:6 was in supratentorial, 1 in the pineal region, 1 in the pons, 1 in the cerebellopontine. Eight patients underwent surgical resection at the first diagnosis, with 6 cases of total resection, 1 case of partial resection, and 1 case of biopsy. One case was misdiagnosed as a germinoma in the pineal region at the initial. After recurrence, surgical resection was performed to confirm the pathology as ETMR. One case was misdiagnosed as glioblastoma during the first surgery. The initial treatment for 4 patients after surgery was radiotherapy combined with concurrent chemotherapy. Recurrence patterns: 2 cases were intracranial dissemination, 2 cases were local recurrence, 1 was spinal cord dissemination. One patient did not receive treatment after surgery and tumor recurrence 3 months later. Survival analysis: The median survival time was 20 months. The 1-year progression-free survival rate (PFS) and overall survival rate (OS) were 22% and 61%, and the 2-year overall survival rate (OS) was 31%.</div></div><div><h3>Conclusion</h3><div>ETMR has a low incidence and poor prognosis. It is easy to misdiagnose and NGS is necessary to assist diagnosis when needed. More effective treatment methods need to be explored.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e10"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624036137","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Embryonal Tumors of the Central Nervous System with Multilayered Rosettes (ETMR) are rare, and there's no standard treatment protocol. This article reports on the current treatment status and prognosis of ETMR in our hospital.

Methods

We retrospectively collected patients with ETMR who received treatment in the Oncology Department of Guangdong sanjiu Brain Hospital from January 2017 to January 2021, analyzed their clinical data.

Results

Among 31 cases of central nervous system embryonic tumors (excluding medulloblastoma and ATRT), 9 (29.03%) were ETMR. The median age at diagnosis was 3 years old (1-15), and the male to female ratio was 4:5. Among them, 5 cases were accompanied by C19MC gene variation. Tumor location:6 was in supratentorial, 1 in the pineal region, 1 in the pons, 1 in the cerebellopontine. Eight patients underwent surgical resection at the first diagnosis, with 6 cases of total resection, 1 case of partial resection, and 1 case of biopsy. One case was misdiagnosed as a germinoma in the pineal region at the initial. After recurrence, surgical resection was performed to confirm the pathology as ETMR. One case was misdiagnosed as glioblastoma during the first surgery. The initial treatment for 4 patients after surgery was radiotherapy combined with concurrent chemotherapy. Recurrence patterns: 2 cases were intracranial dissemination, 2 cases were local recurrence, 1 was spinal cord dissemination. One patient did not receive treatment after surgery and tumor recurrence 3 months later. Survival analysis: The median survival time was 20 months. The 1-year progression-free survival rate (PFS) and overall survival rate (OS) were 22% and 61%, and the 2-year overall survival rate (OS) was 31%.

Conclusion

ETMR has a low incidence and poor prognosis. It is easy to misdiagnose and NGS is necessary to assist diagnosis when needed. More effective treatment methods need to be explored.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多层莲座型中枢神经系统胚胎性肿瘤9例报告
目的中枢神经系统胚胎性肿瘤伴多层玫瑰花结(ETMR)较为罕见,目前尚无标准的治疗方案。本文报道了我院ETMR的治疗现状及预后。方法回顾性收集2017年1月至2021年1月在广东省三九脑科医院肿瘤科接受治疗的ETMR患者,分析其临床资料。结果31例中枢神经系统胚胎肿瘤(不包括髓母细胞瘤和ATRT)中,ETMR 9例(29.03%)。诊断时中位年龄为3岁(1 ~ 15岁),男女比例为4:5。其中5例伴有C19MC基因变异。肿瘤部位:幕上6例,松果体1例,脑桥1例,脑桥小脑1例。首次诊断行手术切除8例,其中全切除6例,部分切除1例,活检1例。1例最初被误诊为松果体区域的生殖细胞瘤。复发后行手术切除以确认病理为ETMR。1例首次手术时被误诊为胶质母细胞瘤。4例患者术后初始治疗为放疗联合化疗。复发类型:颅内播散2例,局部复发2例,脊髓播散1例。1例术后未接受治疗,3个月后肿瘤复发。生存分析:中位生存时间为20个月。1年无进展生存率(PFS)和总生存率(OS)分别为22%和61%,2年总生存率(OS)为31%。结论etmr发病率低,预后差。易误诊,需要时需要NGS辅助诊断。需要探索更有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Defining Stereotactic Body Radiation Therapy: A (Hi)story of Precision and Accuracy. Accelerated Partial Breast Irradiation: The Search for the Optimal Technique Continues. From Constraints to Confidence: A Roadmap of 'Simple' SBRT for Low-Resource Clinical Environments. In Regard to Facondo et al. From Innovation to Evidence: The Middle Age of Stereotactic Body Radiation Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1